Schopick Psychiatry

Schopick Psychiatry in Portsmouth, New Hampshire offers Spravato (esketamine) for treatment-resistant depression and for major depressive disorder with acute suicidal ideation. Led by Dr. David Schopick, who is board certified in adult, adolescent, and child psychiatry and FDA-licensed to dispense Spravato, the practice provides this mechanistically distinct treatment for patients who have not responded to conventional antidepressants.

As an NMDA receptor antagonist that modulates glutamatergic signaling, Spravato can produce rapid antidepressant effects, with many patients experiencing relief within hours to days. It is administered as a 56mg or 84mg intranasal spray under direct medical supervision, followed by a mandatory two-hour observation period managed by the clinical team.

Treatment is typically initiated twice weekly for four weeks, then gradually tapered based on clinical response. The practice serves New Hampshire, southern Maine, and northern Massachusetts.